Botanix Pharmaceuticals' (ASX:BOT) stock slump is backed by no "good" company-specific reason aside from broader macroeconomic factors, said Euroz Hartleys in a Thursday note.
The stock has seen continuous sessions of losses since it reported a wider fiscal first-half loss of AU$0.017 per diluted share, wider compared with a loss of AU$0.0038 a year earlier.
The research firm believes the company's half-year results were unsurprising, and the extent of the stock's decline remains "puzzling."
The company will see a negligible financial impact from the newly imposed 25% tariff on Canadian exports, the note added.
The research firm maintained its buy rating and price target of AU$0.55 on Botanix Pharmaceuticals.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。